Full Protocol Guide

MOTS-c 20mg

A mitochondrial-derived peptide research entry for metabolic stress and exercise-response context.

MOTS-c 20mg product vial
MOTS-c 20mg vial Performance, Recovery & Muscle
ProductMOTS-c 20mg
CategoryPerformance, Recovery & Muscle
FormatMOTS-c 20mg vial
ReviewSource-linked guide

Contents

Use this guide as a structured review page. The same headings appear for every protocol so clients and the care team can scan the page consistently.

Quickstart Highlights

MOTS-c is a 16–amino-acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation[1][2]. Preclinical studies show it enhances insulin sensitivity, promotes fat oxidation, improves exercise capacity, and counters age-related metabolic decline[1][4]. No clinical trials have been completed in humans to date[8]. This educational protocol presents a once-daily subcutaneous approach with gradual titration.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
  • Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
  • Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 200 mcg (0.2 mg) 3 units (0.03 mL)
Weeks 3–4 400 mcg (0.4 mg) 6 units (0.06 mL)
Weeks 5–6 600 mcg (0.6 mg) 9 units (0.09 mL)
Weeks 7–8 800 mcg (0.8 mg) 12 units (0.12 mL)
Weeks 9–10+ 1,000 mcg (1.0 mg) 15 units (0.15 mL)
  • Frequency: Inject once daily subcutaneously[7]. Stay at each dose level for approximately 2 weeks before increasing, and monitor for any adverse reactions[7].
  • For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

Evidence context (important): The table above is a conversion aid for a 5 mg vial reconstituted to 3.0 mL. It is not a clinical recommendation. Published MGF literature is largely preclinical (e.g., muscle and cardiocerebral models) and uses local or systemic routes distinct from subcutaneous daily regimens.[1][3][4][5][6]

  • Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • Inject slowly down the vial wall; avoid foaming.
  • Gently swirl/roll until dissolved (do not shake vigorously).
  • Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  • Use within 7 days for optimal potency[7]. Open source

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (MOTS-C, 20 mg each):
  • Peptide Vials (MOTS-C, 20 mg each):: 8 weeks ≈ 2 vials
  • Peptide Vials (MOTS-C, 20 mg each):: 12 weeks ≈ 3 vials
  • Peptide Vials (MOTS-C, 20 mg each):: 16 weeks ≈ 5 vials
  • Insulin Syringes (U‑100):
  • Insulin Syringes (U‑100):: Per week: 7 syringes (1/day)
  • Insulin Syringes (U‑100):: 8 weeks: 56 syringes
  • Insulin Syringes (U‑100):: 12 weeks: 84 syringes
  • Insulin Syringes (U‑100):: 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.: Per week: 14 swabs (2/day)
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Protocol Overview

Concise summary of the once‑daily regimen.

  • Goal: Support metabolic homeostasis, insulin sensitivity, and age-related physical performance based on preclinical evidence[1][2][4]. Open source
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 200–1,000 mcg daily with gradual titration over 10 weeks.
  • Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach based on animal-to-human extrapolation.

  • Start: 200 mcg daily for 2 weeks.
  • Titration: Increase by ~200 mcg every 2 weeks: 400 mcg (Weeks 3–4), 600 mcg (Weeks 5–6), 800 mcg (Weeks 7–8).
  • Target: Up to 1,000 mcg (1.0 mg) daily by Weeks 9–10+ if well tolerated[7]. Open source
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality and potency.

  • Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; include desiccant if available to minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); peptide degrades rapidly at room temperature (~25% activity loss after 24 hours at 4 °C)[7]. Use within 7 days for best potency. Open source
  • Aliquoting: Prepare single-use aliquots and freeze at −20 °C (−4 °F) if needed; avoid freeze–thaw cycles.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container[11]. Open source
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy[11]. Open source
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose, injection site, and any observations to maintain consistency.
  • Discontinue use and consult a medical professional if any concerning symptoms arise.

How This Works

MOTS-c functions as a metabolic “stress signal” that helps optimize energy usage during nutrient stress or exercise[2]. Its primary mechanism is AMPK activation through inhibition of the folate cycle, causing accumulation of AICAR (an AMP analog)[1][2]. Activated AMPK shifts cells into an energy-efficient mode – enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis[2].

  • MOTS-c can also translocate to the cell nucleus under stress conditions and upregulate antioxidant and stress-response genes[2]. This retrograde signaling from mitochondria to nucleus increases expression of cytoprotective enzymes, helping cells cope with oxidative stress. Research indicates MOTS-c may also modulate mTOR and inflammatory pathways, contributing to lifespan and healthspan effects[10]. Its actions resemble those of exercise and metformin at a cellular level[2], making it of great interest for metabolic disorders, obesity, and aging research.

Lifestyle Factors

Complementary strategies for best outcomes based on MOTS-c’s metabolic mechanisms.

  • Pair with a balanced, protein-forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity to reinforce metabolic adaptations and AMPK signaling[4][8]. Open source
  • Prioritize sleep (7–9 hours) and stress management to support mitochondrial health and recovery.
  • Consider intermittent fasting or caloric restriction, which may synergize with MOTS-c’s AMPK-mediated effects.

Potential Benefits & Side Effects

Observations from preclinical literature (no human clinical trials completed to date)[8]:

  • Metabolic Health: Improves insulin sensitivity and glucose metabolism in mouse models; prevents diet-induced insulin resistance[1][7]. Open source
  • Weight & Fat Reduction: Prevents obesity and reduces visceral fat in obese mice through increased energy expenditure and fat oxidation[1][7]. Open source
  • Post-Menopausal Metabolism: Mitigates metabolic decline in ovariectomized mice; prevents menopause-related fat gain and insulin resistance[3]. Open source
  • Physical Performance: Enhances exercise capacity and counters age-related frailty; old mice ran 2× longer on treadmill tests[4][7]. Open source
  • Organ Protection: Reduces liver fat accumulation, improves cardiac function, and may support cognitive function in preliminary studies[2][7]. Open source
  • Bone & Immunity: Promotes osteoblast activity, inhibits osteoclast formation; modulates immune aging and protects pancreatic islet cells in autoimmune diabetes models[5][10]. Open source
  • Safety: No adverse effects reported in preclinical studies; human tolerability unknown. A modified analog (CB4211) showed good tolerability in a Phase 1 trial[7]. Open source
  • Note: These benefits have been demonstrated only in controlled research settings (mice or cells). Translation to humans requires clinical studies.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[9][11]:

  • Clean the vial stopper and skin with alcohol; allow to dry completely.
  • Pinch a skinfold; insert the needle at 90° (45° if very lean) into subcutaneous tissue[11]. Open source
  • Do not aspirate for subcutaneous injections; inject slowly and steadily over a few seconds[9]. Open source
  • Withdraw needle at the same angle; apply gentle pressure if bleeding occurs (do not rub).
  • Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to avoid irritation and lipohypertrophy[11]. Open source
  • Dispose of used syringes immediately in a proper sharps container (never reuse needles)[11]. Open source

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

  • Do not start, stop, combine, or change a protocol based only on website content.
  • Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

Reference-derived details for MOTS-c 20mg.

  • MOTS-C (20 mg Vial) Open source
  • Cell Metabolism (2015) — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.) View Source Open source
  • Journal of Translational Medicine (2023) — Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.) View Source Open source
  • Journal of Molecular Medicine (2019) — MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction (Lu H, Wei M, Zhai Y, et al.) View Source Open source
  • Nature Communications (2021) — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.) View Source Open source
  • Frontiers in Physiology (2023) — Role of MOTS-c in the regulation of bone metabolism (Yi X, Hu G, Yang Y, et al.) View Source Open source
  • International Journal of Molecular Sciences (2022) — MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases (Mohtashami Z, Singh MK, Salimiaghdam N, et al.) View Source Open source
  • Cognitive Vitality Reports (2021) — MOTS-c (Cognitive Vitality Profile) – Alzheimer’s Drug Discovery Foundation (ADDF) View Source Open source
  • USADA Spirit of Sport (2023) — What is the MOTS-c peptide? – U.S. Anti-Doping Agency education article View Source Open source
  • CDC Vaccine Administration Guidelines — Subcutaneous route technique (angle, site selection, no aspiration) View Source Open source
  • Experimental & Molecular Medicine (2025) — Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Kong BS, Lee H, L’Yi S, et al.) View Source Open source
  • MedlinePlus Medical Encyclopedia (2023) — Subcutaneous (SQ) injections – Patient instructions for proper technique View Source Open source
  • Subcutaneous Drug Injection Review (PMC) — Literature review of factors influencing subcutaneous injection pharmacology View Source Open source
  • Prime Lab Peptides — MOTS-C (20 mg) product page (quality and batch documentation) View Source